Vidac Pharma Holding PLC: Possible Cooperation with Johnson & Johnson

Presentation of Possible Cooperation with Johnson & Johnson at Basel Launch's "Beyond the Needle"

London (pta019/23.10.2025/14:42 UTC+2)

Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology company pioneering first-in-class therapies targeting the unique metabolism of cancer cells, nnounced that its leadership team, Dr. Max Herzberg, Chairman and CEO, and Dr. Eyal Breitbart, Chief Technology Officer, will participate in Basel Launch's "Beyond the Needle: Building the Future of Intratumoral Oncology" event, to be held in Basel, Switzerland, on November 23–24, 2025.

During the event, Vidac Pharma's leadership was invited to a dedicated one-on-one meeting with senior group of representatives from Johnson & Johnson to discuss the evolving landscape of intratumoral oncology and explore possible collaboration models if any in the development of novel therapeutic modalities.

"Vidac Pharma's participation in this high-level forum highlights the growing interest in our novel mode of action, which modulates the tumor microenvironment to become pro-immune and reactivates apoptosis within cancer cells," said Dr. Max Herzberg, Chairman and CEO of Vidac Pharma. "Our upcoming dialogue with Johnson & Johnson will present our belief that our technology has the potential to complement ongoing efforts in intratumoral cancer therapy, and our looking forward to exploring potential new avenues of collaboration with innovative partners across the industry."

The "Beyond the Needle" event, organized by Basel Launch, convenes leading innovators, investors, and pharmaceutical executives to explore emerging technologies enabling precise intratumoral delivery and localized cancer treatment. Vidac Pharma continues to advance its clinical and preclinical pipeline focused on modulating the VDAC-HK2 complex, a central regulator of cancer cell metabolism and survival, with the goal of transforming how solid tumors are treated.

For more information please contact:

About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), while interim results in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.

Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

(end)

Emitter:	Vidac Pharma Holding PLC 20-22 Wenlock Road N1 7GU London United Kingdom
Contact Person:	Sandra Gamzon
Phone:	+972 544 999951
E-Mail:	investors@vidacpharma.com
Website:	www.vidacpharma.com
ISIN(s):	GB00BM9XQ619 (Share)
Stock Exchange(s):	Free Market in Berlin, Hamburg, Stuttgart